NCT02921022 2025-11-26
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
Clinical Trials
7 trialsNCT01839487 2020-07-20
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 2 Completed
NCT04058964 2020-03-13
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03481920 2019-08-22
A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer
PH Research, S.L.
Phase EARLY_PHASE1 Terminated
NCT03634332 2019-05-07
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
Pancreatic Cancer Research Team
Phase 2 Unknown
NCT02910882 2019-04-11
HALO-IST
Scripps Health
Phase 2 Terminated
NCT01453153 2018-11-30
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
Halozyme Therapeutics
Phase 1/2 Completed